These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30648428)

  • 1. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
    Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
    BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding new experimental arms to randomised clinical trials: Impact on error rates.
    Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
    Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
    Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
    Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An optimised multi-arm multi-stage clinical trial design for unknown variance.
    Grayling MJ; Wason JMS; Mander AP
    Contemp Clin Trials; 2018 Apr; 67():116-120. PubMed ID: 29474933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.
    Choodari-Oskooei B; Parmar MK; Royston P; Bowden J
    Trials; 2013 Jan; 14():23. PubMed ID: 23343147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
    Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
    Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flexible implementations of group sequential stopping rules using constrained boundaries.
    Burington BE; Emerson SS
    Biometrics; 2003 Dec; 59(4):770-7. PubMed ID: 14969454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
    Sydes MR; Parmar MK; Mason MD; Clarke NW; Amos C; Anderson J; de Bono J; Dearnaley DP; Dwyer J; Green C; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann G; James ND
    Trials; 2012 Sep; 13():168. PubMed ID: 22978443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some recommendations for multi-arm multi-stage trials.
    Wason J; Magirr D; Law M; Jaki T
    Stat Methods Med Res; 2016 Apr; 25(2):716-27. PubMed ID: 23242385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
    Bratton DJ; Phillips PP; Parmar MK
    BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-arm group sequential designs with a simultaneous stopping rule.
    Urach S; Posch M
    Stat Med; 2016 Dec; 35(30):5536-5550. PubMed ID: 27550822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.
    Jaki T; Hampson LV
    Stat Med; 2016 Feb; 35(4):522-33. PubMed ID: 26456537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design--a reanalysis of 4 trials.
    Barthel FM; Parmar MK; Royston P
    Trials; 2009 Apr; 10():21. PubMed ID: 19374739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-arm multi-stage clinical trials for time-to-event outcomes.
    Dixit V; Mitra P; Simonsen K
    J Biopharm Stat; 2021 Nov; 31(6):838-851. PubMed ID: 34606418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-arm multi-stage survival trial design with arm-specific stopping rule.
    Wu J; Li Y; Zhu L; Patni T
    J Biopharm Stat; 2024 Sep; ():1-12. PubMed ID: 39282887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.